Preclinical Dose-Formulation Stability - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Preclinical Dose-Formulation Stability
When designing stability protocols, formulation, storage, and dosing conditions must be assessed.


Pharmaceutical Technology
Volume 36, Issue 6

Stability considerations

Stability assessments of preclinical dosing formulations need to consider conditions that are representative of the formulation process used for preparing the dose preparation. Specifically, preparations manufactured in an analytical laboratory to evaluate method performance may not be representative of the process used in the formulation laboratory and, therefore, may not be appropriate for use in assessing stability. Differences in scale, equipment, and mixing methods may need to be considered. For example, heat generated from the use of high-speed mixers in a dosing batch may not have been apparent during the preparation of a small-scale batch. As such, direct heating of the dosing batch may be required. Extended or overnight mixing times also may be required for a dosing batch where they may not be required for a small-scale validation batch. These variables need to be considered when establishing an appropriate stability protocol to ensure stability batches are representative of dosing batches.

Stability data need to cover the conditions encountered during dosing in the in vivo studies. Related to dosing, physical stability becomes just as crucial as chemical stability. Questions related to maintaining a viable suspension or homogeneous mixture during the dosing period may need to be considered and addressed. In situations where dosing formulations have known stability issues, either chemical or physical adjustments may be needed for dosing. Conditions such as preparing the dose formulation under yellow light, temperature control, continuous stirring, and timed dosing are all strategies that may be used to ensure that the integrity of the dosing formulation material remains intact. For example, a dose formulation was found to be chemically stable for 48 hours at ambient temperature and observed recoveries were near 100% of the time-zero value. An optimal dosing viscosity, however, could not be maintained at ambient temperature and the material required heating before and during dosing. As a consequence, heating was incorporated into the original stability assessment.

Storage considerations

Consistent with stability assessment for drug products, storage of preclinical dose formulations needs to be considered when evaluating stability. This evaluation may range from a simple assessment of material at ambient or refrigerated conditions or for material being used over multiple dosing days and include evaluation of freeze/thaw cycles. Extensive stability programs, comparable to those designed for drug substances and drug products, are not required as storage and use are tightly controlled.

Stability studies on dose formulations are required to support preclinical regulated studies. While stability protocols for preclinical dose formulations are not as comprehensive as their subsequent drug-substance and drug-product programs, the information they provide to support an in vivo study is critical. Development of stability studies requires consideration of formulation, dosing, and storage to ensure the stability data collected are directly relevant to the in vivo study conditions.

Amy Smith is director of analytical laboratory operations, and Melissa Whitsel is analytical manager both with MPI Research; headquarters located at 54943 North Main Street, Mattawan, MI 49071.

Sources

1. FDA, 21 CFR Part 58 Good Laboratory Practice Regulations Final Rule (Rockville, MD, 1987).

2. M.B. Whitmire, AAPS Jrnl. 12 (4), (2010).

3. ICH, Q1A(R2) Stability Testing of New Drug Substances and Products (2003).

4. ICH, Q2(R1) Validation of Analytical Procedures: Text and Methodology (1996).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
24%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
44%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here